RegeneRx Biopharmaceuticals is a clinical-stage, biopharmaceutical company engaged in the design, research, and development of novel peptides targeted at diseases. It focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. It has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation for medical indications that may be treated by systemic administration.